Gbotosho G O, Happi C T, Sijuade A, Ogundahunsi O A T, Sowunmi A, Oduola A M J
Malaria Research Laboratories, Institute of Advanced Medical Research and Training, College of Medicine, University College Hospital, Ibadan, Nigeria.
Ann Trop Med Parasitol. 2008 Jan;102(1):3-9. doi: 10.1179/136485908X252179.
Although, in in-vitro and limited in-vivo studies, chlorpheniramine (CP) and promethazine (PR) have each been shown to reverse chloroquine (CQ) resistance, the pharmacokinetic basis of this reversal has not been fully elucidated. In the present study, 15 healthy volunteers were randomly allotted to receive standard doses of CQ alone or in combination with CP or PR. Blood samples were collected from each volunteer at 21 time-points, from immediately before to 168 h after the initial dose. These samples were used to follow the changes in the plasma and erythrocytic concentrations of CQ. The ratio between the mean maximum CQ concentration in the erythrocytes and that in the plasma was 4.2 for the volunteers given CQ alone, 7.3 in those given CQ-CP, and 3.2 in those given CQ-PR. CP significantly enhanced the erythrocytic accumulation of CQ, increasing the maximum CQ concentration observed in the erythrocytes by 24% (P = 0.02). The bio-availability of CQ was also significantly increased in the presence of CP, with the mean value for the area under the curve, of erythrocytic concentration v. time, increasing from 99,921 to 214,516 ng/ml.h (P=0.001). The mean half-life of CQ in the erythrocytes also increased when CP was used, from 51 to 100 h, but this change was not statistically significant (P=0.83). In contrast to CP, PR had no statistically significant effect on the disposition of CQ. As CP clearly enhances disposition of CQ, a combination of CQ with CP may be useful in the management of CQ-resistant infections. Detailed toxicological studies are required to understand the full clinical implications of CP's elevation of erythrocytic CQ concentrations.
虽然在体外和有限的体内研究中,已分别证实氯苯那敏(CP)和异丙嗪(PR)可逆转氯喹(CQ)耐药性,但这种逆转的药代动力学基础尚未完全阐明。在本研究中,15名健康志愿者被随机分配,分别接受标准剂量的单独CQ,或CQ与CP或PR的联合用药。在最初给药前至给药后168小时的21个时间点,采集每位志愿者的血样。这些样本用于追踪CQ在血浆和红细胞中的浓度变化。单独给予CQ的志愿者,红细胞中CQ的平均最大浓度与血浆中CQ的平均最大浓度之比为4.2;给予CQ-CP的志愿者为7.3;给予CQ-PR的志愿者为3.2。CP显著增强了CQ在红细胞中的蓄积,使红细胞中观察到的CQ最大浓度增加了24%(P = 0.02)。在CP存在的情况下,CQ的生物利用度也显著增加,红细胞浓度-时间曲线下面积的平均值从99,921增加到214,516 ng/ml.h(P = 0.001)。使用CP时,CQ在红细胞中的平均半衰期也从51小时增加到100小时,但这一变化无统计学意义(P = 0.83)。与CP相反,PR对CQ的处置无统计学显著影响。由于CP明显增强了CQ的处置,CQ与CP联合使用可能有助于治疗CQ耐药感染。需要进行详细的毒理学研究,以了解CP提高红细胞内CQ浓度的全部临床意义。